206 related articles for article (PubMed ID: 15328177)
1. Vaccination with Ep-CAM protein or anti-idiotypic antibody induces Th1-biased response against MHC class I- and II-restricted Ep-CAM epitopes in colorectal carcinoma patients.
Mosolits S; Markovic K; Frödin JE; Virving L; Magnusson CG; Steinitz M; Fagerberg J; Mellstedt H
Clin Cancer Res; 2004 Aug; 10(16):5391-402. PubMed ID: 15328177
[TBL] [Abstract][Full Text] [Related]
2. Immunization of colorectal carcinoma patients with a recombinant canarypox virus expressing the tumor antigen Ep-CAM/KSA (ALVAC-KSA) and granulocyte macrophage colony- stimulating factor induced a tumor-specific cellular immune response.
Ullenhag GJ; Frödin JE; Mosolits S; Kiaii S; Hassan M; Bonnet MC; Moingeon P; Mellstedt H; Rabbani H
Clin Cancer Res; 2003 Jul; 9(7):2447-56. PubMed ID: 12855617
[TBL] [Abstract][Full Text] [Related]
3. Natural T-cell response against MHC class I epitopes of epithelial cell adhesion molecule, her-2/neu, and carcinoembryonic antigen in patients with colorectal cancer.
Nagorsen D; Keilholz U; Rivoltini L; Schmittel A; Letsch A; Asemissen AM; Berger G; Buhr HJ; Thiel E; Scheibenbogen C
Cancer Res; 2000 Sep; 60(17):4850-4. PubMed ID: 10987297
[TBL] [Abstract][Full Text] [Related]
4. T-cell receptor BV gene usage in colorectal carcinoma patients immunised with recombinant Ep-CAM protein or anti-idiotypic antibody.
Mosolits S; Markovic K; Fagerberg J; Frödin JE; Rezvany MR; Kiaii S; Mellstedt H; Jeddi-Tehrani M
Cancer Immunol Immunother; 2005 Jun; 54(6):557-70. PubMed ID: 15570423
[TBL] [Abstract][Full Text] [Related]
5. Immunogenicity of recombinant GA733-2E antigen (CO17-1A, EGP, KS1-4, KSA, Ep-CAM) in gastro-intestinal carcinoma patients.
Staib L; Birebent B; Somasundaram R; Purev E; Braumüller H; Leeser C; Küttner N; Li W; Zhu D; Diao J; Wunner W; Speicher D; Beger HG; Song H; Herlyn D
Int J Cancer; 2001 Apr; 92(1):79-87. PubMed ID: 11279610
[TBL] [Abstract][Full Text] [Related]
6. Human anti-idiotypic antibodies induced a humoral and cellular immune response against a colorectal carcinoma-associated antigen in patients.
Fagerberg J; Steinitz M; Wigzell H; Askelöf P; Mellstedt H
Proc Natl Acad Sci U S A; 1995 May; 92(11):4773-7. PubMed ID: 7539133
[TBL] [Abstract][Full Text] [Related]
7. Targeting human Ep-CAM in transgenic mice by anti-idiotype and antigen based vaccines.
Mosolits S; Campbell F; Litvinov SV; Fagerberg J; Crowe JS; Mellstedt H; Ellis JH
Int J Cancer; 2004 Nov; 112(4):669-77. PubMed ID: 15382049
[TBL] [Abstract][Full Text] [Related]
8. Immunization of colorectal cancer patients with recombinant baculovirus-derived KSA (Ep-CAM) formulated with monophosphoryl lipid A in liposomal emulsion, with and without granulocyte-macrophage colony-stimulating factor.
Neidhart J; Allen KO; Barlow DL; Carpenter M; Shaw DR; Triozzi PL; Conry RM
Vaccine; 2004 Jan; 22(5-6):773-80. PubMed ID: 14741172
[TBL] [Abstract][Full Text] [Related]
9. Functional detection of epithelial cell adhesion molecule specific cytotoxic T lymphocytes in patients with lung cancer, colorectal cancer and in healthy donors.
Trojan A; Tun-Kyi A; Odermatt B; Nestle FO; Stahel RA
Lung Cancer; 2002 May; 36(2):151-8. PubMed ID: 11955649
[TBL] [Abstract][Full Text] [Related]
10. Genetic vaccines against Ep-CAM break tolerance to self in a limited subset of subjects: initial identification of predictive biomarkers.
Elia L; Mennuni C; Storto M; Podda S; Calvaruso F; Salucci V; Aurisicchio L; Scarito A; Ciliberto G; La Monica N; Palombo F
Eur J Immunol; 2006 May; 36(5):1337-49. PubMed ID: 16619291
[TBL] [Abstract][Full Text] [Related]
11. Differences in T-cell immunity toward tumor-associated antigens in colorectal cancer and breast cancer patients.
Nagorsen D; Scheibenbogen C; Schaller G; Leigh B; Schmittel A; Letsch A; Thiel E; Keilholz U
Int J Cancer; 2003 Jun; 105(2):221-5. PubMed ID: 12673683
[TBL] [Abstract][Full Text] [Related]
12. Vaccination of metastatic colorectal cancer patients with matured dendritic cells loaded with multiple major histocompatibility complex class I peptides.
Kavanagh B; Ko A; Venook A; Margolin K; Zeh H; Lotze M; Schillinger B; Liu W; Lu Y; Mitsky P; Schilling M; Bercovici N; Loudovaris M; Guillermo R; Lee SM; Bender J; Mills B; Fong L
J Immunother; 2007 Oct; 30(7):762-72. PubMed ID: 17893568
[TBL] [Abstract][Full Text] [Related]
13. Identification of an epitope from the epithelial cell adhesion molecule eliciting HLA-A*2402-restricted cytotoxic T-lymphocyte responses.
Tajima K; Demachi A; Ito Y; Nishida K; Akatsuka Y; Tsujimura K; Kuwano H; Mitsudomi T; Takahashi T; Kuzushima K
Tissue Antigens; 2004 Dec; 64(6):650-9. PubMed ID: 15546337
[TBL] [Abstract][Full Text] [Related]
14. Pharmacological administration of granulocyte/macrophage-colony-stimulating factor is of significant importance for the induction of a strong humoral and cellular response in patients immunized with recombinant carcinoembryonic antigen.
Samanci A; Yi Q; Fagerberg J; Strigård K; Smith G; Rudén U; Wahren B; Mellstedt H
Cancer Immunol Immunother; 1998 Nov; 47(3):131-42. PubMed ID: 9829838
[TBL] [Abstract][Full Text] [Related]
15. Generation of cytotoxic T lymphocytes against native and altered peptides of human leukocyte antigen-A*0201 restricted epitopes from the human epithelial cell adhesion molecule.
Trojan A; Witzens M; Schultze JL; Vonderheide RH; Harig S; Krackhardt AM; Stahel RA; Gribben JG
Cancer Res; 2001 Jun; 61(12):4761-5. PubMed ID: 11406549
[TBL] [Abstract][Full Text] [Related]
16. Clinical effects of a chimeric anti-EpCAM monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor in patients with metastatic colorectal carcinoma.
Liljefors M; Nilsson B; Fagerberg J; Ragnhammar P; Mellstedt H; Frödin JE
Int J Oncol; 2005 Jun; 26(6):1581-9. PubMed ID: 15870873
[TBL] [Abstract][Full Text] [Related]
17. Identification of potential HLA-A *0201 restricted CTL epitopes derived from the epithelial cell adhesion molecule (Ep-CAM) and the carcinoembryonic antigen (CEA).
Ras E; van der Burg SH; Zegveld ST; Brandt RM; Kuppen PJ; Offringa R; Warnarr SO; van de Velde CJ; Melief CJ
Hum Immunol; 1997 Mar; 53(1):81-9. PubMed ID: 9127151
[TBL] [Abstract][Full Text] [Related]
18. Targeting CD4(+) T-helper cells improves the induction of antitumor responses in dendritic cell-based vaccination.
Aarntzen EH; De Vries IJ; Lesterhuis WJ; Schuurhuis D; Jacobs JF; Bol K; Schreibelt G; Mus R; De Wilt JH; Haanen JB; Schadendorf D; Croockewit A; Blokx WA; Van Rossum MM; Kwok WW; Adema GJ; Punt CJ; Figdor CG
Cancer Res; 2013 Jan; 73(1):19-29. PubMed ID: 23087058
[TBL] [Abstract][Full Text] [Related]
19. A neoadjuvant clinical trial in colorectal cancer patients of the human anti-idiotypic antibody 105AD7, which mimics CD55.
Durrant LG; Maxwell-Armstrong C; Buckley D; Amin S; Robins RA; Carmichael J; Scholefield JH
Clin Cancer Res; 2000 Feb; 6(2):422-30. PubMed ID: 10690519
[TBL] [Abstract][Full Text] [Related]
20. Protective immunity against human carcinoembryonic antigen (CEA) induced by an oral DNA vaccine in CEA-transgenic mice.
Xiang R; Silletti S; Lode HN; Dolman CS; Ruehlmann JM; Niethammer AG; Pertl U; Gillies SD; Primus FJ; Reisfeld RA
Clin Cancer Res; 2001 Mar; 7(3 Suppl):856s-864s. PubMed ID: 11300483
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
